Growing up in poverty may influence the wiring of a child’s brain, study suggests

Ex­elix­is has set­tled a patent dis­pute over Te­va’s at­tempt to mar­ket a gener­ic ver­sion of its block­buster can­cer drug Cabome­tyx, push­ing gener­ic com­pe­ti­tion in­to the

Share this article According to GlobalData’s company profile on Bristol-Myers Squibb, Cancer treatment biomarkers was a key innovation area identified from patents. Bristol-Myers Squibb‘s grant